Skip to main content
. 2018 Apr 27;9(32):22559–22570. doi: 10.18632/oncotarget.25176

Figure 3. Overall survival.

Figure 3

(A) Entire cohort by mutation status at diagnosis. (B) Entire cohort by clinical stage at diagnosis (TNM staging). (C) All patients with mutation(s) by clinical stage at diagnosis (TNM staging). (D) All patients without mutations by clinical stage at diagnosis (TNM staging). (E) Patients with EGFR and ALK tumors by Clinical stage at diagnosis (TNM staging). (F) Patients with stage IV at diagnosis by presence of brain metastases at diagnosis. (G) Patients with EGFR-mutant positive tumors by the type of mutation – exon 19 deletion vs. L858R exon 21 insertion. (H) Patients with EGFR-mutant tumors and brain metastases at diagnosis by the type of mutation – exon 19 deletion vs. L858R exon 21 insertion.